ProShares UltraShort Nasdaq Biotechnology

BIS provides -2x exposure to a market-cap-weighted index of biotechnology and pharmaceutical companies listed on the NASDAQ.

Manager Directed Portfolios - iM DBi Managed Futures Strategy ETF

KFA Mount Lucas Index Strategy ETF

Technical analysis can tell investors a lot about both stocks and ETFs, including when some might have been overbought, or even oversold.

3 ETFs in “Oversold” Territory to Start the Week

Invesco NASDAQ Internet ETF

Inverse leveraged biotech ETF and internet ETF traded with an outsized volume on Friday.

2 ETFs to Watch for Outsized Volume on Internet & Inverse Leveraged Biotech

ProShares Short Dow30

ProShares UltraShort Oil & Gas

ProShares UltraShort Dow30

ProShares Short MidCap400

ProShares UltraShort MidCap400

ProShares Short QQQ

ProShares UltraShort QQQ

ProShares Short Real Estate

ProShares UltraShort Technology

ProShares Short Russell2000

ProShares UltraShort Health Care

ProShares Short SmallCap600

PrShs UlSh CnSr Shs

ProShares UltraShort SmallCap600

ProShares UltraPro Short Dow30

ProShares UltraShort Utilities

ProShares UltraShort S&P500

ProShares Short Financials

ProShares Short S&P500

ProShares UltraShort Industrials

ProShares UltraShort Financials

ProShares UltraPro Short MidCap400

ProShares UltraShort Basic Materials

ProShares UltraPro Short S&P500

ProShares UltraPro Short QQQ

ProShares UltraShort Real Estate

ProShares UltraPro Short Russell2000

Proshares Ultrashort Semiconductors

ProShares UltraShort Consumer Goods

ProShares UltraShort Russell2000

We are bearish on all American bear market ETFs. Measuring the purchase levels of short ETFs replaces the old, odd lot and total short selling indicators so popular in the 1960s, 70s and 80s.

Purchase Levels Of 31 Short ETFs Signal Bear Market Bottom (Technical Analysis)

ProShares Ultra Nasdaq Biotechnology

Invesco Nasdaq Biotechnology ETF

The biotechnology industry is a bifurcated space. In one corner, you have nascent, small-cap companies that don't yet have steady revenue streams because their new drug or treatment is still in development, hasn't received FDA approval, or hasn't been in the market long enough to establish a proven track record.

Cap-Weighting Crucial When Indexing Biotech

News for ProShares UltraShort Nasdaq Biotechnology ETF (BIS)